Therapeutic Strategies in Advanced Ovarian Cancer

Therapeutic Strategies in Advanced Ovarian Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: Surgery in Early-Stage Ovarian Cancer

July 26th 2018

EP. 2: Chemotherapy in Early-Stage Ovarian Cancer

July 26th 2018

EP. 3: Molecular Testing in Ovarian Cancer

July 26th 2018

EP. 4: Surgical Controversies in Advanced Ovarian Cancer

July 26th 2018

EP. 5: Neoadjuvant Therapy in Advanced Ovarian Cancer

July 26th 2018

EP. 6: Targeting VEGF in Advanced Ovarian Cancer

July 26th 2018

EP. 7: Advanced Ovarian Cancer: Emerging Therapies

July 26th 2018

EP. 8: Using Novel Therapies in Advanced Ovarian Cancer

July 26th 2018

EP. 9: The GOG-0213 Trial in Recurrent Ovarian Cancer

July 26th 2018

EP. 10: A New Standard of Care in Recurrent Ovarian Cancer?

July 26th 2018

EP. 11: PARP Maintenance Therapy in Recurrent Ovarian Cancer

July 26th 2018

EP. 12: Using Maintenance Therapy in Recurrent Ovarian Cancer

July 26th 2018

EP. 13: Recurrent Ovarian Cancer: PARP Inhibitors Compared

July 26th 2018

EP. 14: Ongoing PARP Trials in Recurrent Ovarian Cancer

July 26th 2018

EP. 15: PARP Combination Therapies in Ovarian Cancer

July 26th 2018

EP. 16: Novel Treatment Strategies in Recurrent Ovarian Cancer

July 26th 2018

EP. 17: Improvements in Advanced Ovarian Cancer

July 26th 2018

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026

Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma